Catalyst
Slingshot members are tracking this event:
Cynapsus plans to initiate a pivotal clinical program evaluating the safety and efficacy of APL-130277 in PD patients in the fourth quarter of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CYNA | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 29, 2016
Occurred Source:
https://globenewswire.com/news-release/2016/08/29/867552/0/en/Cynapsus-Receives-FDA-Fast-Track-Designation-for-APL-130277-for-the-Treatment-of-OFF-Episodes-in-Patients-with-Parkinson-s-Disease.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Apl-130277, Parkinson’s Disease
